| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1435-100MG | Amlexanox | 100mg | $84.00 | |
| GBM-1435-500MG | Amlexanox | 500mg | $210.00 |
| Bioassays Specification | |
| Bio-Activity | TBK1 inhibitor; Antidiabetic |
| Chemical Name | 2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid |
| Function / Pharmacology | Improves obesity-related metabolic dysfunction in mouse models1. Increases thermogenesis and weight loss, decreases steatosis and improves insulin sensitivity. Inhibits TANK-binding kinase 1 (TBK1) and IKKε (IC50=1.2 M)2. Clinically useful in the treatment of aphthus ulcers3. Inhibits prostate tumor metastasis by targeting IKKε/TBK1/NFκB signaling4. |
| CAS# | 68302-57-8 |
| MW | 298.3 |
| Molecular Formula | C16H14N2O4 |
| Solubility | Soluble in DMSO (up to 60 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1. L Koch Nat. Rev. Endocrinol. 2013 9:185 2. SM Reilly et al. Nat. Med. 2012 19:313 3. SA Nasry et al. J. Clin. Exp. Dent. 2016 8:e517 4. C Cheng et al. Theranostics 2018 8:4633 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | TBK1 inhibitor; Antidiabetic |
| Chemical Name | 2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid |
| Function / Pharmacology | Improves obesity-related metabolic dysfunction in mouse models1. Increases thermogenesis and weight loss, decreases steatosis and improves insulin sensitivity. Inhibits TANK-binding kinase 1 (TBK1) and IKKε (IC50=1.2 M)2. Clinically useful in the treatment of aphthus ulcers3. Inhibits prostate tumor metastasis by targeting IKKε/TBK1/NFκB signaling4. |
| CAS# | 68302-57-8 |
| MW | 298.3 |
| Molecular Formula | C16H14N2O4 |
| Solubility | Soluble in DMSO (up to 60 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1. L Koch Nat. Rev. Endocrinol. 2013 9:185 2. SM Reilly et al. Nat. Med. 2012 19:313 3. SA Nasry et al. J. Clin. Exp. Dent. 2016 8:e517 4. C Cheng et al. Theranostics 2018 8:4633 |
| Protein Specification | |
| Purity | >98% |
